TRIMTECH Therapeutics signs $411m Biogen deal for protein degraders

The biotech company will collaborate with Biogen to develop small molecule protein degraders for neurodegenerative diseases, leveraging its proprietary TRIM21-based targeted protein degradation technology

Cambridge-based biotechnology company TRIMTECH Therapeutics has entered a strategic research collaboration with Biogen to develop small molecule protein degraders for neurodegenerative diseases, in a deal with potential payments of up to $411m, plus royalties.

The research collaboration, option and licence agreement will combine TRIMTECH’s proprietary TRIM21-based targeted protein degradation (TPD) technology with Biogen’s expertise in developing treatments for neurological conditions.

Under the agreement, the companies will work together to discover and develop small molecule degraders targeting proteins associated with neurodegenerative diseases.

Biogen will have the option to exercise a global exclusive licence to the resulting degraders, after which it will assume responsibility for further development and commercialisation.

TRIMTECH is eligible to receive up to $32m in upfront and research milestone payments, with additional development and commercial milestones bringing the total potential value to $411m, alongside royalties.

Dr Nicki Thompson, CEO of TRIMTECH Therapeutics, said the agreement marked a significant milestone for the company and validated its TRIM21-based degradation platforms.


The company's technology is built around TRIM21, an E3 ubiquitin ligase that can be harnessed to selectively target and remove toxic protein aggregates and oligomers while preserving functional forms of the proteins.

Its proprietary TRIMTAC and TRIMGLUE platforms comprise small molecule degraders designed to access the central nervous system (CNS), potentially opening up new therapeutic approaches for conditions including Alzheimer's and Parkinson's disease.


TRIMTECH expands funding and research capabilities

The Biogen agreement follows a period of significant growth for TRIMTECH. In June, the company secured an additional $14m in seed financing, bringing its total seed funding to $47m.

The extension was led by Johnson & Johnson Innovation – JJDC and BGF, joining existing investors including Cambridge Innovation Capital, the Dementia Discovery Fund, Pfizer Ventures and Eli Lilly.

Earlier in 2026, TRIMTECH also expanded from the Milner Therapeutics Institute's Bio-incubator to the Babraham Research Campus in Cambridge, supporting its next phase of development.

The company established a scientific advisory board in September last year, appointing targeted protein degradation specialists Professor Alessio Ciulli and Dr Adam Gilbert to help guide its technology and therapeutic pipeline.

Trending Articles

You may also like